Guangdong Zhongsheng Pharmaceutical Co.,Ltd.

The company was founded in 1979 and listed on the Shenzhen Stock Exchange in 2009. It is one of the top 100 Chinese pharmaceutical industry enterprises dedicated to human health. The company implements the value of “patient interests first”, adheres to the corporate tenet of “caring for life with quality products and serving the healthy public with quality”, and is based in the fields of ophthalmology, cardiovascular, respiratory, digestive and other treatments. It has ten subsidiaries and four major production bases, and is committed to becoming a first-class medical and health industry group in China. The company is a high-tech enterprise integrating R&D, production and sales of pharmaceuticals. Main products: Compound thrombotron series products, brain embolism capsules, compound salvia tablets, zongsheng pill series products, heat-clearing and dehumidifying granules, liritvir tablets, carboxymethane oral solution (tablets), cefixime dispersible tablets, cefixime dispersible tablets, adenosine monophosphate monophosphate, isoniazid tablets, pyrazinamide tablets, ethambutol hydrochloride tablets, rifampicin capsules, ribavirin tablets, aluminum sulfide oral suspension, pralofen eye drops Tine eye drops, diquafinxol eye drops, bromfenac sodium eye drops, loratadine tablets, clemastine fumarate oral solution. Company honors: In recent years, the company has successively won the 2019 “Top 100 Most Innovative Pharmaceutical Companies in the Asia-Pacific Region” (No. 26 in the SME list), the top 100 innovative Chinese pharmaceutical enterprises, the best industrial enterprise in China's pharmaceutical R&D product line, the most growing enterprise in the Chinese pharmaceutical industry, the top 100 Chinese pharmaceutical brand enterprises, and the 2021 China Pharmaceutical R&D Product Line Best Industrial Enterprise”.